Merck (US)–Evercore: investor conference, 202311 supply service Merck participates in Evercore ISI HealthCONx Conference 2023

	Period	2023-11-30
	Partner, 1st	Merck Research Laboratories
	Group	Merck (US) (MSD) (Group)
	Partner, 2nd	Evercore ISI
	Group	Evercore (Group)
	Product	Evercore ISI HealthCONx Conference 2023 Miami
	Product 2	pharmaceutical
	Person	Barr, Eliav (Merck (US) 202311 SVP Head of Global Clinical Development + CMO at Merck Research Laboratories)

Merck & Co., Inc.. (11/20/23). "Press Release: Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference". Rahway, NJ.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, is scheduled to participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Thursday, Nov. 30, 2023, at 1:20 p.m. ET.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Media:

Robert Josephson
(203) 914-2372
[email protected]

Michael Levey
(215) 872-1462
[email protected]

Investors:

Peter Dannenbaum
(732) 594-1579
[email protected]

Steven Graziano
(732) 594-1583
[email protected]